Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com

Role of Myeloperoxidase as A Biomarker in Early Diagnosis of Sepsis in Pediatric Intensive Care Unit in Beni-Suef University Hospital

Dalia Saber Morgan[1], Heba Mostafa Ahmed[1], Nesreen Mostafa Kamel Taha[2], Mahmoud Mohammed Abd Elkhalek Hodeib[1], Karima Sobhy Abdelrhman Ahmed[1*]

1Department of Pediatrics, Faculty of Medicine - Beni-Suef University
2 Department of Clinical and Chemical Pathology, Faculty of Medicine - Beni-Suef University

Corresponding author: Karima Sobhy Abdelrhman Ahmed

Cite this paper as: Karima Sobhy Abdelrhman Ahmed (2024) Role of Myeloperoxidase as A Biomarker in Early Diagnosis of Sepsis in Pediatric Intensive Care Unit in Beni-Suef University Hospital . *Frontiersin Health Informatics, 13* (3), 5582-5592

Abstract
Sepsis is a critical disorder that impacts numerous kids, regardless of existing health issues. Sepsis is considered one of the primary effects of mortality in kids, especially in developed nations. Sepsis is a life-threatening illness that impacts numerous children, regardless of existing health issues. Sepsis is considered one of the major reasons for mortality in kids, especially in developed nations. Despite demographic statistics not indicating it, numerous kids claimed to have died from other underlying diseases or died of sepsis directly. Systemic inflammatory response syndrome (SIRS) is a clinical condition resulting from inflammation, distinguished by tachypnea, fever, tachycardia, & leukocytosis. SIRS may result from a non-infectious inflammatory trigger or sepsis, such as polytrauma, surgical procedures, burns, or pancreatitis. It is essential to differentiate between sepsis & non-infectious systemic inflammatory response syndrome, as prompt antibiotic therapy is essential for sepsis survival. Myeloperoxidase (MPO) is a heme protein included within the azurophilic granules of neutrophils. Myeloperoxidase synthesizes hypochlorous a` & other reactive oxidants to phagocytoze ingested bacteria. Myeloperoxidase is a crucial element of innate immunity & a primary factor in the neutrophilic response to bacterial invasion. Neutrophils are the initial type of cell to respond in the host immunological response. Initiated neutrophils release their contents of granule, including myeloperoxidase, into the plasma. Myeloperoxidase may serve as a diagnostic biomarker to distinguish among SIRS without sepsis and infection.
Key words: *Sepsis, Myeloperoxidase, SIRS*

Introduction

Sepsis is the main affect of mortality globally among kids, resulting in around 7.5 million fatalities per year. It involves the leading 4 reasons for kids death as identified by the World Health Organization (WHO): severe diarrhea, pneumonia, measles, & malaria. In the United States, seventy-two thousand kids are hospitalized for sepsis, with a stated death rate of twenty-five percent and an estimated economic cost of $4.8 billion [1].

For myeloperoxidase to serve as a useful biomarker, it must be accurately detectable in the relevant specimen. Myeloperoxidase can be identified using many ways, which are also or direct specific indirect approaches. Direct approaches utilize commercially accessible immunoassays antibodies, such as Western blotting, microscopy, or ELISA. Cytochemical staining is often achieved through the use of myeloperoxidase substrates (such as., o-dianisidine, 3,3′-diaminobenzidine), which metabolize upon the addition of H2O2 to produce colored products, generally red brown in hue. The utilization of H2O2 via an H2O2 electrode is feasible, although one must account for competing reactions with catalase. [3]

Indirect detection emphasizes the byproducts of myeloperoxidase, primarily hypochlorous a` (HOCl), regarded as the principal physiological result of myeloperoxidase. Hypochlorous a` may oxidize amino a`, including tyrosine,

resulting in the formation of 3-chloro-tyrosine [4]. 3,5-Dichlorotyrosine is a stable & viable detection product, however less frequently utilized. Additional intermediates, including chlorinated nucleosides, lipid chlorohydrins, glutathione sulfonamide, & protein carbonyls, are potentially prospective biomarkers [5]. 2-Chlorofatty a` were shown to be identifiable in sepsis & sepsis-related acute respiratory distress syndrome models [6].
The objective of this investigation was to find out the role of myeloperoxidase as a biomarker for the early identification of sepsis in the Pediatric Intensive Care Unit and its prognostic significance for death.

Sepsis

Physiological variables unique to kids' patients rendered previous attempts to modify adult sepsis criteria futile. Kids and adults exhibit physiological differences, susceptibility to illnesses, and infection sites, requiring distinct diagnostic criteria and therapeutic approaches. Globally, forty-nine percent of kids who develop sepsis possess a comorbid disease that leaves them to get infection. The prevalent comorbidities in kids who acquire sepsis are age-specific: babies may have chronic lung disorder or CHD, kids aged one to nine often present with underlying neuromuscular disorders, and adolescents frequently have pre-existing malignancy. [7]

Defining Sepsis

Before 2005, standardized criteria for pediatric sepsis were absent, leading to variations in sepsis research. In 2005, the Pediatric Sepsis Consensus Congress (PSCC) met to define the concept of sepsis; nevertheless, like the adult population, this definition requires continuous modification and reconsideration as research in the area progresses. Defining sepsis in kids' patients is complicated by age-specific vital signs & their significant physiological reserve, which often obscures the severity of their illness. The Pediatric Sepsis Consensus Congress categorized age into 6 distinctive groups to consider age-specific vital signs and risk factors for invasive infections, which subsequently influence antibiotic coverage requirements [8]. Pediatric severe sepsis is characterized by (1) the presence of 2 or more criteria for systemic inflammatory response syndrome, (2) a suspected or confirmed invasive infection, & (3) acute respiratory distress syndrome, cardiovascular dysfunction, or 2 or more organ dysfunctions. [9]
Currently, no single biomarker has demonstrated sufficient specificity or sensitivity to diagnose sepsis or predict outcomes in specific groups. Like adult sepsis investigations, there is active study investigating both research & clinical measures relevant to the kid's population. The implementation of biomarkers or "-omic" information, which includes transcriptomics, genomics, proteomics, & metabolomics, may be an existing instrument that may be accessible soon. This information may provide prognostic and diagnostic capability early during sepsis [10]. This information may assist in categorizing this varied case population into subgroups for more customized therapeutic strategies. Evidence already exists that genetic, proteomic, transcriptomic, and metabolomic data can indicate people likely had more benefit or severe clinical courses from medications. [11]

Response to Infection by the Developing Immune System

A kid's immune system significantly differs from that of adults regarding adaptive & innate immunological functions; complete immunologic maturation isn't attained till adolescence [12]. The move from a sterile environment of intrauterine to the changing and complex microbiological environment that the newborn faces during life requires significant alterations in immune function. Neonates exhibit significant immunological compromise, characterized by relatively inadequate adaptive and innate immune responses [13]. This provides a survival benefit as a more suppressed immune system enables the infant to deal with the previously sterile skin & GIT colonization with typical bacterial flora without prompting a significant inflammatory reaction [14]. In newborns, phagocytes exhibit reduced responsiveness to pathogen-corrolelated molecular patterns (PAMPs) compared to adult cells, possess less adhesion & extravasation capabilities, release low pro-inflammatory cytokines, & demonstrate decreased antigen presentation activity to adaptive immune cells. Natural killer (NK) cells have lowered cytotoxicity, & complement levels range from ten to seventy percent of those found in adults. [13]

Epidemiology & Clinical Manifestations of Pediatric Sepsis

The assessed overall occurrence of severe sepsis amongst kids in the US rose consistently from 0.56 cases per one thousand kids in 1995 to 0.63 cases per one thousand kids in 2000 and further to 0.89 patient per one thousand kids in 2005, primarily caused by newborn sepsis. The calculated occurrence of sepsis is 9.7 per thousand in US

newborns, 2.25 per 1,000 in non-newborn infants, and ranges from 0.23 to 0.52 per one thousand kids aged one to nineteen years. This distinction at the early stages of life reflects the significantly elevated rates observed in improved old cases relative to younger adults. The clinical presentation of sepsis for cases aged from eighteen to thirty is significantly like that observed in those aged twelve to seventeen while significantly distinct from the profile of cases aged sixty-five and older. Like adults, the common microorganisms responsible for sepsis in children depend on geographical location, age, and medical comorbidities [16].

In late-onset sepsis newborns, the predominant bacterial pathogens are enteric gram-negative rods & group B streptococci, particularly Escherichia coli. Protocols for peripartum prophylaxis have diminished the occurrence of group B streptococci -correlated sepsis. Bordetella pertussis can induce a severe disease in young babies, marked by recurring episodes of apnea, gagging, bradycardia, and cyanosis, with elevated death in cases that progress to pulmonary hypertension & respiratory failure.[19]

Neisseria meningitidis is another bacterium frequently identified in newborns & young kids suffering from severe sepsis in developed nations [20]. N. meningitidis infection, resulting in meningococcemia, exhibits a distinct bimodal age distribution, initially affecting toddlers and infants, followed by an increase in adolescents, particularly during school outbreaks. This has led to recommendations for the administration of the conjugate vaccine of meningococcal for adolescents & debates amongst experts concerning potential strategies of vaccination for babies [21]. Meningococcemia typically manifests in previously healthy kids, often characterized by the sudden development of vomiting, fever, severe myalgias, headache, & difficulty focused [22]. The classic triad of meningismus, fever, & impaired status of mental is present in merely twenty-seven percent of kids with meningococcemia [23]. Up to twenty-five percent of infants with meningococcemia may advance to purpura fulminans, resulting from microvascular thrombosis that causes skin infarction, tissue necrosis, and bleeding. Kids with gangrene and tissue necrosis can need severe amputations. Additional etiologies of purpura fulminans involve S. pyogenes, S. pneumoniae, and varicella. [24]

Sepsis induced by viruses can arise from several viral agents, determined by age and other immunological conditions. Influenza is a prevalent cause of viral sepsis in kids, resulting in a significant percentage of hospitalizations and the highest death rate. Despite vaccination's capacity to prevent the worst respiratory infections associated with influenza, low rates of vaccination, diminished vaccine efficacy in young kids, & cases of poor alignment among circulating viruses & the vaccine of influenza contribute to a persistent healthcare problem. While the parainfluenza virus mainly impacts the upper airway, leading to cough primarily in healthy kids, it can induce severe pneumonia in infants & kids with impaired immune or respiratory systems, like adenovirus [25].

Diarrheal infections represent a significant sepsis etiology in kids & babies, particularly in the developed world. Public health sanitation measures & access to clean water are critical & significantly efficient in reducing sepsis-related death among kids globally. In developed countries, rotavirus can cause severe diarrhea and a sepsis-like condition in infants, requiring the creation of the rotavirus vaccination [26].

Numerous other infections induce sepsis predominantly in developing nations. A sepsis syndrome characterized by rupture of capillary & disseminated intravascular coagulation (DIC) is caused by the mosquito-borne flavivirus, a dengue virus that is endemic to numerous tropical countries [27]. Malaria, especially Plasmodium falciparum, can induce sepsis in young & human immunodeficiency virus -infected kids; sepsis frequently occurs alongside cerebral malaria, manifesting as changed status of mental, acidosis, & convulsions. Burkholderia pseudomallei, the causative agent of the illness, prevalent in Southeast Asia, may manifest lung symptoms and fever. [28]

Primary & Acquired Immune Deficiency in Sepsis

Neonates, young kids, & infants are at a heightened probability for severe infections & sepsis than older kids & teens; thus, it is essential to identify severe clinical manifestations or recurring infection patterns that may indicate a causal immune system deficiency. A full assessment for a 1ry immune deficiency involves an extensive medical history, including birth, gestation, development, growth, & immunizations, with a familial history & a record of previous infections, with a focus on recognized pathogens and infection sites. Screening labs may then be evaluated with specialist consultation. [30]

Management of Sepsis in Babies & Kids

The early pediatric sepsis treatment has primarily been derived from sepsis in adult research, & only recently have prospective investigations on sepsis in pediatrics been conducted. Consequently, the protocols of management for

sepsis in pediatrics remain preliminary and need evaluation through extensive multi-institutional prospective research. Despite its limitations, compliance with the existing sepsis of pediatric recommendations, as described in the pediatric segment of the Surviving Sepsis Campaign, correlates with enhanced results. Nevertheless, many investigations have reported inadequate compliance, with just forty-five percent of teams in a simulated emergency department accurately following all six-sepsis metrics [31]. The establishment of protocols has constantly improved adherence to published guidelines. The formulation of protocols can enhance treatment by creating electronic order sets & clinical pathways to accelerate fluid & antibiotic delivery while also fostering nursing education, possibly resulting in decreased mortality [8].

Protocol-driven resuscitation bundles have demonstrated a reduction in the time to initiate treatment (including early fluids, antimicrobial treatment, & vasoactive support), which correlates with enhanced results [32]. Retrospective cohort research implemented the greatest practice alert in the emergency department to enhance early detection & observed significant improvements in time-to-intervention. This resulted in a reduction in the frequency of acute kidney injury, the necessity for renal replacement treatment, hospital length of stay (LOS), pediatric intensive care unit (PICU) length of stay, & mortality [33].

Fluid resuscitation must be vigorous, with boluses of twenty milliliters per kilogram of crystalloid delivered over five to ten minutes either intraosseous or intravenous access. Owing to the great physiological reserve of young cases, hypotension frequently doesn't manifest until the case approaches cardiovascular collapse. Consequently, blood pressure is an insufficient endpoint for resuscitation; the resuscitation of cases with severe sepsis must be adjusted based on improving urine output, consciousness level, & achieving normal capillary refill while avoiding rales or hepatomegaly [32]. Aggressive & early resuscitation of fluid has demonstrated a reduction in mortality rates [11]. In contrast, delayed fluid resuscitation was related to prolonged ICU & hospital length of stay, & heightened occurrence of acute kidney injury. Despite similar total quantities of fluid resuscitation, a reduced time to implementation led to a lower frequency of acute kidney injury & its related mortality and morbidity [33]. Notwithstanding this evidence, the advantages of existing protocols of fluid resuscitation have lately been scrutinized, requiring further investigation [34]. If the case remains to be hypotensive after reaching these clinical benchmarks, inotropic support must be begun since it has demonstrated a reduction in fatality rates. Inotropes may be initiated peripherally until central access is established. Additionally, twenty-five percent of kids with septic shock exhibit adrenal insufficiency & may advantage from corticosteroid management; the presence of purpura, previous steroid treatment, & established adrenal & pituitary abnormalities must raise clinical suspicion [32]. Corticosteroid therapy must be quickly initiated when clinically indicated; early administration (less than eight hours) has been related to reduced mortality, whereas delays in treatment (less than seventy-two hours) correlate with heightened adverse events without similar mortality benefits. [35]

Influences Influencing Pediatric Sepsis-Related Death

Kids younger than twelve months exhibit the greatest risk of fatality from sepsis, mostly due to the elevated frequency of sepsis & the significant percentage of sepsis-correlated fatalities among infants born extremely preterm. Infants exhibit the maximum frequency of severe sepsis compared to older kids; however, a significant part is viral, & the majority will survive hospitalization. Studies indicate that whereas adult and animal research suggests that mortality is greater among male patients, this pattern is less prominent in children, yet boys are more frequently hospitalized during infancy for severe infections. The prevalence of malignancies & other chronic respiratory & cardiac disorders in kids increases with age, contributing to sepsis-correlated death; most older kids hospitalized with sepsis possess underlying diseases that weaken their cardiorespiratory or immune systems. [20]

Outcomes

Information on long-term mortality and chronic morbidity in the pediatric Septic population is limited. The application of early research utilizing conflicting definitions of sepsis is restricted, yet sepsis survivors are known to frequently experience permanent neurocognitive and neuropsychological impairments [36]. A retrospective chart study based on ICD-9 codes projected mortality at ten to twenty percent; nevertheless, recent prospective research utilizing consensus criteria reported a death rate of twenty-five percent for severe sepsis. [35]

Future Directions

A recent investigation revealed a significant discrepancy among physician-identified sepsis & consensus criteria sepsis, demonstrating the deficiencies of our present definitions & previous retrospective administrative data-based

investigations. A definition of sepsis that is more inclusive in terms of the clinician's assessment of what defines septic would be necessary. The most successful therapy regimen is going to be determined by evaluating the therapy and results for these subjects in large prospective research. A great deal of resources will be necessary for growing this information. The SPROUT assessment predicted that an interventional study capable of detecting a five percent decrease in death would necessitate 2,118 kids with severe sepsis. Additionally, they assessed that the investigation would necessitate ≥58 PICUs and take three years to complete [37]**.** Consequently, it is essential to assess additional clinically significant results in as well as death in the hospital. Long-term mortality and morbidity necessitate research as well as acute outcomes.

Myeloperoxidase

The innate immune system is significantly influenced by mammalian heme peroxidases, like lactoperoxidase (LPO), eosinophil peroxidase (EPO), and myeloperoxidase (MPO), which can produce reactive oxidants that aid in the killing of yeasts, bacteria, parasites, fungi, & other pathogenic organisms that invade [38].

The myeloperoxidase protein is a tetramer with a entire calculated molecular weight of one hundred fifty thousand kilodaltons. The tetramer consists of 2 halves (hemi-myeloperoxidase), which consists of 2 heavies (approximately sixty kilodaltons) & two light (approximately fifteen kilodaltons) components. In the past, a range of molecular weights had been identified between 120,000 and one hundred sixty thousand kilodaltons. Subsequent sections give more precise masses. Human myeloperoxidase has been found to comprise 467 amino a` in the long chain & 105 amino a` in the small chain. [39].

It is distinctive in the family of peroxidase enzyme; anywhere myeloperoxidase has 3 covalently correlated amino a` linkages from the chain of protein to the protoporphyrin IX (HAEM) active site [40]. The 5th coordination iron site is working by the group of imidazole histidine, similarly to other peroxidases. The 3 amino acids bonded to the hemoglobin are correlated to its green color, as the myeloperoxidase was formerly named verdoperoxidase (Agner, 1940). A curious observation indicated that a protein known as “spleen green” protein was like myeloperoxidase. Site-directed mutation investigations of myeloperoxidase demonstrated that the Met243 → Gln mutation altered the haem absorption peak to 410 nanometers, a blue shift of roughly twenty nanometers from the original peak at 429 nanometers that look like other peroxidases. The sulfonium bond formed by Met243 with the haem causes a distortion of binding of ligand & planarity properties that's unique to myeloperoxidase [41]**.**

Myeloperoxidase is a glycoprotein.

It is important to observe myeloperoxidase glycosylation and its impact on structure and function in accordance with the recent developments in glycomics. Myeloperoxidase contains thirty-eight glycopeptides, and all 5 predicted glycosylation sites have been observed as glycosylated. These sites are N-linked glycosylation sites because they contain an asparagine residue (Asn355, Asn323, Asn483, Asn729, & Asn391) [42]. Characterization of myeloperoxidase glycosylation sites has been conducted in an additional investigation [43]. Specific critical amino a`, all of which are Asn residues, are glycosylated: Asn355, Asn322, Asn483, Asn391, & Asn729. The glycosylation involved paucimannose (Asn483) & phosphorylated N-glycans (Asn323). The glycosylation masses are relatively like earlier results, even though these full investigations have provided a more precise myeloperoxidase mass picture [44].

Physiological roles of hemoperoxidases.

Mammalian hemoperoxidases are primarily released and synthesized by myeloid cells, with monocytes, neutrophils, & certain tissue macrophages acting as the 1ry sources. In response to chemical signals, a significant neutrophils number, & at a later stage, macrophages and monocytes, are attracted to sites of inflammation & infection. They are activated by both bacteria-derived stimuli & signals released by other host cells. The pathogens ingestion by these phagocytes leads to the presence of a higher concentration of myeloperoxidase in compartments of phagolysosomal [45].

Consequences of myeloperoxidase interactions with & extracellular molecules oxidation.

Exposure to exogenous hypochlorous acid or myeloperoxidase enzymatic systems may lead to myeloperoxidase-mediated oxidation, which may modulate the function and activity of biomolecules in cells. A variety of types of mammalian cells were utilized to investigate the in vitro reactivity of hypochlorous acid [46], yeast, and bacteria [47]**.** This oxidant is highly toxic and has the potential for inducing cellular damage, aberrant signaling, and dysfunction through a variety of processes that are relevant to the progression of inflammatory illness. Nevertheless,

the extracellular species oxidation by myeloperoxidase can additionally have significant impacts on cell function & activity may be of pathological significance. This is because extracellular alterations may "signal" to cells, modify their behavior, & impair intracellular reactions. These components are further observed below. The impacts of myeloperoxidase on the function and activity of extracellular biomolecules, in addition to the resulting impacts on cells, might be either positive or negative. These impacts may include modest and specific alterations, gross alterations (like inter - or intra -molecular cross-links & fragmentation), & signaling impacts [46].

Cross-linking & aggregation of proteins.

Covalent and non-covalent interactions may result in the formation of protein cross-links & aggregates. Proteins perform this process to a significant extent; however, it appears to happen to a limited extent in other biomolecules. The oxidation of protein Cys residues to disulfides is an important factor contributing to the formation of (reversible) covalent links. However, hypochlorous acid may additionally produce other reversible cross-links, including sulfenamides. Formation of inter-protein disulfide was associated with a deficiency in the activity of enzyme; however, direct Cys residues oxidation in the active site is additionally a frequent cause of activity of enzyme, especially in cells [48]. The inter-protein disulfides formation could happen extracellularly, as evidenced by the cross-linking of the S100A9 & S100A8 monomers of calprotectin, a greatly abundant (more than sixty percent by mass) cytosolic protein of neutrophils that is released upon activation of cells [49]. The antifungal and antibacterial functions of this protein are affected by the deficiency of the zinc-, iron-, & manganese-ion binding capacities that result from cross-link formation, which improved the calprotectin susceptibility to proteolysis [50]**.** Nevertheless, this cross-linked species was utilized as an indicator of in vivo oxidant damage. It has been identified in the saliva of healthy adults & in the bronchoalveolar lavage fluid of individuals with respiratory illnesses [49].

Fragmentation of carbohydrates, proteins, DNA/RNA, and phospholipids.

Even though hypochlorous acid reacts slowly with the peptide backbone, protein fragmentation may be noted at massive molar excesses of oxidant. The degree of this fragmentation is contingent upon the alternative number (competing) sites of reaction for the oxidant. Fragmentation is a result of a variety of mechanisms, including both non-radical and radical reactions [49].

Alterations in physical properties.

The alterations in structure and function that result from the alterations that happen on the nucleobases of DNA/RNA & the side chains of phospholipids or proteins. Consequently, the steric bulk of these species, as well as a rise in polarity/hydrophilicity & the effect of changed hydrogen bonding interactions, may change inter- & intra-molecular interactions and packing (for example, side chains of fatty a` within DNA/RNA bases, phospholipids, side chains of protein) [51].

Changes in enzymatic activity.

Enzymatic (or other functional) activity is altered by the interaction of myeloperoxidase-derived oxidants with reactive residues that are found in the enzymes active site. The following are a few key examples of enzymes that have been stated to be modulated by oxidative alteration as a consequence of exposure to myeloperoxidase systems and/or hypochlorous acid. The most prevalent outcome is the loss of function, although there are additionally cases of functional improvement. The inactivation of glyceraldehyde-3-phosphate dehydrogenase, protein tyrosine phosphatases, creatine kinase, and kinases, cathepsins, and caspases are all known examples of loss of function in cells. [38]

Modifications in immunogenicity.

Protein change may improve its immunogenicity [52]. This was observed in a variety of proteins, such as serum albumin of bovine & human, yeast alcohol dehydrogenase, & glycoproteins (ovalbumin, human apo-transferrin). Oxidation converts these proteins from low-affinity ligands for endocytic receptors to high-affinity ligands, thereby promoting the degranulation and activation of other leukocytes and neutrophils [53].

Changes in cell proliferation & adhesion induced by modified extracellular matrix.

Modifications have been identified in domains of proteoglycans & extracellular matrix proteins that are critical for extracellular matrix function, including those included in cell & integrin binding, extracellular matrix assembly, & maintenance of 3-dimential structure. Consequently, it isn’t unexpected that these modifications may change the adhesion, proliferation, & function of correlated cells. Hypochlorous acid- or myeloperoxidase-modified ECM or its components demonstrate decreased adherence to both smooth muscle & endothelial cells, which is consistent

with damage observed in these species [54].

Impacts of modified lipoproteins.

There was significant interest in the function of high-density lipoprotein & low-density lipoprotein changes that are prompted by myeloperoxidase-derived oxidants in the atherosclerosis progression. It is widely recognized that myeloperoxidase change enhances the low-density lipoprotein atherogenicity & diminishes the high-density lipoprotein protective properties [55].

Myeloperoxidase usefulness as a biomarker in illness states.

Leukemia.

Myeloperoxidase is a valuable sign for acute myelogenous leukemia. Acute myelogenous leukemia is distinguished by a fast proliferation of myeloid cells and an arrest in their maturation. The identification was initially made only depending on the morphological & pathological investigation of bone marrow & blood. Nevertheless, the French American British group has identified 9 subtypes of acute myelogenous leukemia in response to the increasing understanding of the heterogeneity of the disease. These subtypes are based on the morphologic appearance, specific myeloid lineage, & reactivity with 3 histochemical stains, such as Sudan black, myeloperoxidase, & naphthylbutyrate & nonspecific esterase α-naphthylacetate. Out of the 9 acute myelogenous leukemia subtypes, 6 (M1 to M4, M4EO, & M6) are myeloperoxidase positive. Additionally, its function as a biomarker, myeloperoxidase expression in this illness is correlated with beneficial results [3]**.**

Cardiovascular illnesses.

Myeloperoxidase For approximately two decades, myeloperoxidase was recognized as a critical biomarker in the field of cardiovascular health. Heart failure, hypertension, pulmonary arterial hypertension, acute coronary syndrome, heart transplant, diabetes mellitus, graft rejection, atherosclerosis, & atrial fibrillation are cardiovascular diseases where elevated concentrations of myeloperoxidase were observed [56]. Myeloperoxidase serum levels are a predictor of negative consequences & future cardiovascular events in cases with acute coronary syndrome. Neutrophil and macrophage activity in coronary blood vessel plaques were recognized for some time as a cause of destabilization and oxidation of these lesions. Myeloperoxidase-positive monocytes and neutrophils were identified in unstable lesions within thrombi [57].

Neurodegenerative diseases.

Myeloperoxidase was related to the neuropathology seen in Alzheimer's illness, stroke, multiple sclerosis, depression, Parkinson’s illness, epilepsy, & traumatic brain injury. The peripheral blood myeloperoxidase level seems to correspond with illness progression or severity. In cases with Alzheimer's illness, the peripheral blood level of myeloperoxidase was significantly elevated than in the control group [58]. This biochemical value is indicative of neutrophil activity in this condition. Inhibition of myeloperoxidase in investigational autoimmune encephalitis, a neuroinflammatory autoimmune illness like multiple sclerosis, diminished illness severity.[59]

Autoimmune disorder – idiopathic & drug-induced systemic lupus erythematosus (SLE).

Systemic lupus erythematosus is an autoimmune disorder that may manifest with systemic symptoms or be confined to a particular organ, such as the skin, kidneys, or blood vessels. The profile features of serum are two primary categories of autoantibodies: those targeting nucleus components of cells, such as double-stranded DNA or single-stranded histones, & histone-DNA complexes, known as anti-nuclear antibodies (ANAs). The alternative class of antibodies targets cytoplasmic lysosomal constituents of monocytes & neutrophils, involving enzymes like proteinase-3 & myeloperoxidase. These are collectively referred to as anti-neutrophil cytoplasmic antibodies (ANCAs). In this category, particular antibodies targeting a single protein, namely anti- myeloperoxidase = p- anti-neutrophil cytoplasmic antibodies & anti-proteinase-3 = c- anti-neutrophil cytoplasmic antibodies, were recognized in cases with distinct forms of systemic lupus erythematosus. The detection of these antibodies is utilized to identify specific rare types of vasculitis, including 3 variants of renal nephritis, polyangiitis, & drug-induced vasculitis. [3]

Drug metabolism & Myeloperoxidase inhibition.

Reactions of metabolism of drug facilitated by myeloperoxidase were recognized for an extended period. MPO's classification as a haem enzyme, akin to the P450 enzyme family, indicates its potential for metabolism of drug. The metabolism of medicines by neutrophils, particularly through the coordinated function of NADPH oxidase & myeloperoxidase, is suggested to contribute to their adverse drug reactions and side effects.[60].

The bad side of myeloperoxidase & oxidant formation is tissue damage.

Despite H2O2 being a potent two-electron oxidant (Eo 1.349 V at pH 7) capable of causing cellular damage, it exhibits a delayed reaction rate with most biological targets. In contrast, hypochlorous acid (HOCl), produced by myeloperoxidase, is a weaker oxidant (Eo 1.28 V at pH 7) but works significantly more quickly with several target molecules, exhibiting a constant rate approximately 107-fold greater than those of H2O2. [61]

References

[1] Ruth A, McCracken CE, Fortenberry JD, Hall M, Simon HK, Hebbar KB. Pediatric severe sepsis: current trends and outcomes from the Pediatric Health Information Systems database. Pediatr Crit Care Med. 2014;15(9):828–38.

[2] Weiss SL, Fitzgerald JC, Maffei FA, Kane JM, Rodriguez-Nunez A, Hsing DD, Franzon D, Kee SY, Bush JL, Roy JA. Discordant identification of pediatric severe sepsis by research and clinical definitions in the SPROUT international point prevalence study. Crit care. 2015;19:1–10.

[3] Siraki AG. The many roles of myeloperoxidase: from inflammation and immunity to biomarkers, drug metabolism and drug discovery. Redox Biol. 2021;46:102109.

[4] Kettle AJ. Neutrophils convert tyrosyl residues in albumin to chlorotyrosine. FEBS Lett. 1996;379(1):103–6.

[5] Winterbourn CC, Kettle AJ. Biomarkers of myeloperoxidase-derived hypochlorous acid. Free Radic Biol Med. 2000;29(5):403–9.

[6] Amunugama K, Pike DP, Ford DA. The lipid biology of sepsis. J Lipid Res. 2021;62.

[7] Watson RS, Carcillo JA. Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med. 2005;6(3):S3–5.

[8] Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit care Med. 2005;6(1):2–8.

[9] Weiss SL, Fitzgerald JC, Balamuth F, Alpern ER, Lavelle J, Chilutti M, Grundmeier R, Nadkarni VM, Thomas NJ. Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. Crit Care Med. 2014;42(11):2409–17.

[10] Mathias B, Lipori G, Moldawer LL, Efron PA. Integrating "big data" into surgical practice. Surgery. 2016;159(2):371–4.

[11] Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, Weiss SL, Fitzgerald J, Checchia PA, Meyer K. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med. 2015;191(3):309–15.

[12] Ygberg S, Nilsson A. The developing immune system–from foetus to toddler. Acta Paediatr. 2012;101(2):120–7.

[13] Greene AD, Lang SA, Kendziorski JA, Sroga-Rios JM, Herzog TJ, Burns KA. Endometriosis: where are we and where are we going? Reproduction. 2016;152(3):R63.

[14] Cuenca AG, Wynn JL, Moldawer LL, Levy O. Role of innate immunity in neonatal infection. Am J Perinatol. 2013;30(02):105–12.

[15] Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in the epidemiology of pediatric severe sepsis. Pediatr Crit Care Med. 2013;14(7):686–93.

[16] Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–10.

[17] Vickers NJ. Animal communication: when i'm calling you, will you answer too? Curr Biol. 2017;27(14):R713–5.

[18] Baltimore RS. Consequences of prophylaxis for group B streptococcal infections of the neonate. In: Seminars in perinatology. Elsevier; 2007. p. 33–8.

[19] Berger JT, Carcillo JA, Shanley TP, Wessel DL, Clark A, Holubkov R, Meert KL, Newth CJL, Berg RA, Heidemann S. Critical pertussis illness in children: a multicenter prospective cohort study. Pediatr Crit care Med. 2013;14(4):356–65.

[20] Watson A, Troxler RF, Pena M, Kandil A, Berger J, Rose MC. MUC7 mucin glycoprotein is present in airway secretions of asthmatic, but not control, patients. Am J Respir Crit Care Med. 2003;167(A465).

[21] Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep Recomm Reports. 2013;62(2):1–28.

[22] Sabatini C, Bosis S, Semino M, Senatore L, Principi N, Esposito S. Clinical presentation of meningococcal disease in childhood. J Prev Med Hyg. 2012;53(2):116–9.

[23] Hazelzet JA, Risseeuw-Appe IM, Kornelisse RF, Hop WCJ, Dekker I, Joosten KFM, de Groot R, Hack CE. Age-related differences in outcome and severity of DIC in children with septic shock and purpura. Thromb Haemost. 1996;76(12):932–8.

[24] Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, Yeh T, Kim SS, Cafaro DP, Scannon PJ. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet. 2000;356(9234):961–7.

[25] Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, Simões EAF, Carbonell-Estrany X. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis Ther. 2016;5:271–98.

[26] Scheier mD E, mD PhD SA. Septicemia following rotavirus gastroenteritis. 2013;

[27] Singhi S, Kissoon N, Bansal A. Dengue e dengue hemorrágico: aspectos do manejo na unidade de terapia intensiva. J Pediatr (Rio J). 2007;83:S22–35.

[28] Pagakrong Lumbiganon PL, Surapon Viengnondha SV. Clinical manifestations of melioidosis in children. 1995;

[29] Ballow M. Approach to the patient with recurrent infections. Clin Rev Allergy Immunol. 2008;34:129–40.

[30] Oliveira JB, Fleisher TA. Laboratory evaluation of primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2):S297–305.

[31] Kessler DO, Walsh B, Whitfill T, Gangadharan S, Gawel M, Brown L, Auerbach M. Disparities in adherence to pediatric sepsis guidelines across a spectrum of emergency departments: a multicenter, cross-sectional observational in situ simulation study. J Emerg Med. 2016;50(3):403–15.

[32] Dellinger RP, Levy M, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Aitken L, Al Rahma H, Bernard GR, Biban P, Bion JF, Calandra T, Carcillo JA, Clemmer TP, Divatia J V., Du B, Fujishima S, Gando S, Bruch CG, Guyatt G, Hazelzet JA, Hirasawa H, Hollenberg SM, Jacobi J, Jenkins I, Jimenez E, Jones AE, Kacmarek RM, Kern W, Koh SO, Kotani J, Machado F, Marini J, Marshall JC, Masur H, Mehta S, Muscedere J, Napolitano LM, Parker MM, Parrrillo JE, Qiu H, Randolph AG, Rello J, Resende E, Rivers EP, Schorr CA, Shukri K, Silva E, Soth MD, Thompson AE, Vender JS, Welte T, Zimmerman JL. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013 Feb;39(2):165–228.

[33] Arikan AA, Williams EA, Graf JM, Kennedy CE, Patel B, Cruz AT. Resuscitation bundle in pediatric shock decreases acute kidney injury and improves outcomes. J Pediatr. 2015;167(6):1301–5.

[34] Gelbart B, Glassford NJ, Bellomo R. Fluid bolus therapy-based resuscitation for severe sepsis in hospitalized children: a systematic review. Pediatr Crit Care Med. 2015;16(8):e297–307.

[35] Menon K, Wong HR. Corticosteroids in pediatric shock: a call to arms. Pediatr Crit Care Med. 2015;16(8):e313–7.

[36] Als LC, Nadel S, Cooper M, Pierce CM, Sahakian BJ, Garralda ME. Neuropsychologic function three to six months following admission to the PICU with meningoencephalitis, sepsis, and other disorders: a prospective study of school-aged children. Crit Care Med. 2013;41(4):1094–103.

[37] Balamuth F, Weiss SL, Neuman MI, Scott H, Brady PW, Paul R, Farris RWD, McClead R,

Hayes K, Gaieski D. Pediatric severe sepsis in US children's hospitals. Pediatr Crit Care Med. 2014;15(9):798–805.

[38] Davies MJ, Hawkins CL. The role of myeloperoxidase in biomolecule modification, chronic inflammation, and disease. Antioxid Redox Signal. 2020;32(13):957–81.

[39] Xu Y, Jack Jr CR, O'Brien PC, Kokmen E, Smith GE, Ivnik RJ, Boeve BF, Tangalos RG, Petersen RC. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology. 2000;54(9):1760–7.

[40] Winterbourn CC, Kettle AJ, Hampton MB. Reactive oxygen species and neutrophil function. Annu Rev Biochem. 2016;85(1):765–92.

[41] Raaschou-Nielsen O, Beelen R, Wang M, Hoek G, Andersen ZJ, Hoffmann B, Stafoggia M, Samoli E, Weinmayr G, Dimakopoulou K. Particulate matter air pollution components and risk for lung cancer. Environ Int. 2016;87:66–73.

[42] Ruggiero M, Reinwald H, Pacini S. Is chondroitin sulfate responsible for the biological effects attributed to the GC protein-derived Macrophage Activating Factor (GcMAF)? Med Hypotheses. 2016;94:126–31.

[43] Reiding KR, Bondt A, Hennig R, Gardner RA, O'Flaherty R, Trbojević-Akmačić I, Shubhakar A, Hazes JMW, Reichl U, Fernandes DL. High-throughput serum N-glycomics: method comparison and application to study rheumatoid arthritis and pregnancy-associated changes[S]. Mol Cell proteomics. 2019;18(1):3–15.*

[44] Bensalem S, Soubhye J, Aldib I, Bournine L, Nguyen AT, Vanhaeverbeek M, Rousseau A, Boudjeltia KZ, Sarakbi A, Kauffmann JM. Inhibition of myeloperoxidase activity by the alkaloids of Peganum harmala L.(Zygophyllaceae). J Ethnopharmacol. 2014;154(2):361–9.

[45] Winterbourn CC, Hampton MB, Livesey JH, Kettle AJ. Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome: implications for microbial killing. J Biol Chem. 2006;281(52):39860–9.

[46] Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood, J Am Soc Hematol. 1998;92(9):3007–17.

[47] Carmona-Gutierrez D, Alavian-Ghavanini A, Habernig L, Bauer M, Hammer A, Rossmann C, Zimmermann A, Ruckenstuhl C, Büttner S, Eisenberg T. The cell death protease Kex1p is essential for hypochlorite-induced apoptosis in yeast. Cell cycle. 2013;12(11):1704–12.

[48] Fuentes-Lemus E, Hägglund P, López-Alarcón C, Davies MJ. Oxidative crosslinking of peptides and proteins: Mechanisms of formation, detection, characterization and quantification. Molecules. 2021;27(1):15.

[49] Hoskin TS, Crowther JM, Cheung J, Epton MJ, Sly PD, Elder PA, Dobson RCJ, Kettle AJ, Dickerhof N. Oxidative cross-linking of calprotectin occurs in vivo, altering its structure and susceptibility to proteolysis. Redox Biol. 2019;24:101202.

[50] Magon NJ, Turner R, Gearry RB, Hampton MB, Sly PD, Kettle AJ. Oxidation of calprotectin by hypochlorous acid prevents chelation of essential metal ions and allows bacterial growth: relevance to infections in cystic fibrosis. Free Radic Biol Med. 2015;86:133–44.

[51] Hawkins CL, Davies MJ. Inactivation of protease inhibitors and lysozyme by hypochlorous acid: role of side-chain oxidation and protein unfolding in loss of biological function. Chem Res Toxicol. 2005;18(10):1600–10.

[52] Biedroń R, Konopiński MK, Marcinkiewicz J, Józefowski S. Oxidation by neutrophils-derived HOCl increases immunogenicity of proteins by converting them into ligands of several endocytic receptors involved in antigen uptake by dendritic cells and macrophages. PLoS One. 2015;10(4):e0123293.

[53] Gorudko I V, Grigorieva D V, Shamova E V, Kostevich VA, Sokolov A V, Mikhalchik E V, Cherenkevich SN, Arnhold J, Panasenko OM. Hypohalous acid-modified human serum albumin induces neutrophil NADPH oxidase activation, degranulation, and shape change. Free Radic Biol Med. 2014;68:326–34.

[54] Vanichkitrungruang S, Chuang CY, Hawkins CL, Hammer A, Hoefler G, Malle E, Davies MJ.

Oxidation of human plasma fibronectin by inflammatory oxidants perturbs endothelial cell function. Free Radic Biol Med. 2019;136:118–34.

[55] Sokolov A V, Ageeva K V, Cherkalina OS, Pulina MO, Zakharova ET, Prozorovskii VN, Aksenov D V, Vasilyev VB, Panasenko OM. Identification and properties of complexes formed by myeloperoxidase with lipoproteins and ceruloplasmin. Chem Phys Lipids. 2010;163(4–5):347–55.

[56] Ramachandra CJA, Ja KPMM, Chua J, Cong S, Shim W, Hausenloy DJ. Myeloperoxidase as a multifaceted target for cardiovascular protection. Antioxid Redox Signal. 2020;32(15):1135–49.

[57] Tavora FR, Ripple M, Li L, Burke AP. Monocytes and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques. BMC Cardiovasc Disord. 2009;9:1–7.

[58] Wu CY, Bawa KK, Ouk M, Leung N, Yu D, Lanctot KL, Herrmann N, Pakosh M, Swardfager W. Neutrophil activation in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis of protein markers in blood and cerebrospinal fluid. Ageing Res Rev. 2020;62:101130.

[59] Rossi B, Santos-Lima B, Terrabuio E, Zenaro E, Constantin G. Common peripheral immunity mechanisms in multiple sclerosis and Alzheimer's disease. Front Immunol. 2021;12:639369.

[60] Marx N, Davies MJ, Grant PJ, Mathieu C, Petrie JR, Cosentino F, Buse JB. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. lancet Diabetes Endocrinol. 2021;9(1):46–52.

[61] Davies MJ. Protein oxidation and peroxidation. Biochem J. 2016;473(7):805–25.